معرفی
Dr. Carly Adamson is an Honorary Clinical Research Fellow at the University of Glasgow's School of Cardiovascular & Metabolic Health, affiliated with the British Heart Foundation (BHF) Cardiovascular Research Centre. Her research focuses on heart failure mechanisms, clinical pharmacotherapy, and biomarker-driven outcomes. She has contributed to major trials like DAPA-HF and DELIVER, investigating therapies such as dapagliflozin's efficacy across patient subgroups. Her work spans biomarker discovery (e.g., neuropeptide Y, IGFBP-7), prognostication models (LIFE-HF), and comorbidity impacts on heart failure outcomes. Recent studies address anemia management, self-efficacy in patients, and cardiorenal interactions. Dr. Adamson collaborates extensively with global cardiovascular research networks and publishes in high-impact journals like European Journal of Heart Failure and Circulation.
Research interests emphasize translational cardiology, with a focus on personalized medicine for heart failure. Her articles analyze drug efficacy in diverse populations, including BMI-stratified patient groups and those with preserved ejection fraction. Collaborative projects include the Glasgow Natural History Study of Coronary Interventions (GNOCCI) and meta-analyses of coronary perforation outcomes. She also explores preconception counseling for women with cardiac conditions and the role of inflammatory markers like interleukin-6 in adverse outcomes.
Her work bridges clinical practice and research, addressing gaps in treatment optimization and patient stratification. Recent trends show increasing focus on biomarker-driven prognostication and drug safety profiles, particularly for SGLT2 inhibitors. Dr. Adamson's contributions advance understanding of heart failure pathophysiology and improve evidence-based therapeutic strategies.